Cited by 495Antifungal resistance and susceptibilityFungal Infections and StudiesOcular Infections and Treatments

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects

Rex, John H., Pappas, Peter G., Karchmer, Adolf W., Sobel, Jack, Edwards, John E., Hadley, Susan, Brass, Corstiaan, Vazquez, Jose A. +28 more·2003·Clinical Infectious Diseases

Abstract

A randomized, blinded, multicenter trial was conducted to compare fluconazole (800 mg per day) plus placebo with fluconazole plus amphotericin B (AmB) deoxycholate (0.7 mg/kg per day, with the placebo/AmB component given only for the first 5-6 days) as therapy for candidemia due to species other than Candida krusei in adults without neutropenia. A total of 219 patients met criteria for a modified intent-to-treat analysis. The groups were similar except that those who were treated with fluconazole plus placebo had a higher mean (+/- standard error) Acute Physiology and Chronic Health Evaluation II score (16.8+/-0.6 vs. 15.0+/-0.7; P=.039). Success rates on study day 30 by Kaplan-Meier time-to-failure analysis were 57% for fluconazole plus placebo and 69% for fluconazole plus AmB (P=.08). Overall success rates were 56% (60 of 107 patients) and 69% (77 of 112 patients; P=.043), respectively; the bloodstream infection failed to clear in 17% and 6% of subjects, respectively (P=.02). In nonneutropenic subjects, the combination of fluconazole plus AmB was not antagonistic compared with fluconazole alone, and the combination trended toward improved success and more-rapid clearance from the bloodstream.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/374850

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a single randomized clinical trial comparing high-dose fluconazole versus standard fluconazole dosing and amphotericin B in patients with candidemia, there was a trend in favor of the combination for several outcomes, but the 2 groups had significant differences in baseline APACHE II score favoring the combination arm.

    “For several outcomes there was a trend in favor of the combination; however, the 2 groups had significant differences in baseline APACHE II score favoring the combination arm.”
  • C. albicans infections are typically treated with azole inhibitors of ergosterol biosynthesis, often leading to drug resistance.

    “Infections are typically treated with azole inhibitors of ergosterol biosynthesis often leading to drug resistance.”

    From The evolution of drug resistance in clinical isolates of Candida albicans. (2015) · cites this paper as Rex et al., 2003

  • Fluconazole combined with amphotericin B had a higher overall treatment success rate and a lower rate of failure to clear the bloodstream than fluconazole monotherapy.

    “A study comparing fluconazole monotherapy with fluconazole combined with amphotericin B found a higher overall treatment success rate and a lower rate of failure to clear the bloodstream with the combination regimen [28].”

    From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [28]

  • Patients with the lowest and highest APACHE II scores benefited the least from combination therapy with fluconazole and amphotericin B.

    “Patients with the lowest and highest APACHE II scores benefited the least from combination therapy, suggesting that fluconazole monotherapy is adequate for candidemic patients with mild disease, whereas for the sickest patients, failure rates are high regardless of treatment choice [28].”

    From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [28]

  • Fungemia due to C. glabrata has been treated successfully with fluconazole (6 mg/kg per day).

    “Although fungemia due to C. glabrata has been treated successfully with fluconazole (6 mg/kg per day) [105, 132]”

    From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [132]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., Zervos, M., McKinsey, D., Lee, J., Babinchak, T., Bradsher, R. W., Cleary, J. D., Cohen, D. M., Danziger, L., Goldman, M., Goodman, J., Hilton, E., Hyslop, N. E., Kett, D. H., Lutz, J., Rubin, R. H., Scheld, W. M., Schuster, M., Simmons, B., Stein, D. K., Washburn, R. G., Mautner, L., Chu, T., Panzer, H., Rosenstein, R. B., Booth, J., & the National Institute of Allergy and Infectious Diseases Mycoses Study Group
Affiliations
  • AstraZeneca (United Kingdom) (GB)
  • University of Alabama at Birmingham (US)
  • Beth Israel Deaconess Medical Center (US)
  • Wayne State University (US)
  • Harbor–UCLA Medical Center (US)
  • Buffalo Medical Group (US)
  • University of Mississippi Medical Center (US)
  • Westchester Medical Center (US)
  • Beaumont Health (US)
  • Thomas Jefferson University (US)
  • University of Arkansas for Medical Sciences (US)
  • University of Illinois Chicago (US)
  • Indiana University School of Medicine (US)
  • University of Minnesota (US)
  • Tulane University (US)
  • University of Miami (US)
  • Community Medical Centers (US)
  • Brigham and Women's Hospital (US)
  • University of Virginia (US)
  • Hospital of the University of Pennsylvania (US)
  • Methodist University Hospital (US)
  • Albert Einstein College of Medicine (US)
  • Overton Brooks VA Medical Center (US)
Corresponding author
Rex, John H.
Venue
Clinical Infectious Diseases
Published
2003-05-15
Volume
36
Issue
10
Pages
1221-1228
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W1974953831
Cited by
495
References
18
Citations by year
2026: 4 · 2025: 5 · 2024: 10 · 2023: 2 · 2022: 7 · 2021: 18 · 2020: 11 · 2019: 9 · 2018: 12 · 2017: 10 · 2016: 5 · 2015: 19 · 2014: 19 · 2013: 19 · 2012: 23
FWCI
26.41
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Health and Human Services
  • Pfizer
  • AstraZeneca
  • Brigham and Women's Hospital
  • Wayne State University
  • University of Pennsylvania
  • University of Minnesota
  • Louisiana State University
  • Thomas Jefferson University
  • U.S. Public Health Service (N01-AL-65296)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
  • Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
Keywords
candidemia, fluconazole, amphotericin B deoxycholate, combination antifungal therapy, non-neutropenic patients, treatment failure, drug antagonism
MeSH terms
Adult, Amphotericin B, Antifungal Agents, Candida, Candidiasis, Catheterization, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Neutropenia, Fluconazole, Fungemia, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review